Wissenschaftliche Veröffentlichungen

Orginalberichte
Übersichtsarbeiten
Beiträge zu Fachbüchern
Einladungen zu Vorträgen
Vorträge auf Kongressen
  1. J. Dippel, I. Foeldvari: Therapie der Juvenilen Polyartikulären Chronischen Arthritis. Jahrestagung der Deutschen Gesellschaft für Kinderheilkunde, Ulm 1989.
  2. I. Foeldvari, Y. Kimura, J.C. Jacobs: Macht Komplementdefizienz anfällig für SLE im Kindesalter? 1. Jahrestagung der Deutschen Gesellschaft für Kinderrheumatologie, Göttingen, 1991.
  3. I. Foeldvari: Häufigkeit von Antiphospholipid-Antikörpern bei kinderrheumatologischen Patienten. 2. Jahrestagung der Deutschen Gesellschaft für Kinderrheumatologie, Göttingen, 1992.
  4. I. Foeldvari, C. Loeliger: Auffällige Häufung von Antiphospholipid-Antikörpern bei Eltern von Kindern mit juveniler oligoartikulärer Arthritis und SLE und deren Korrelation mit HLA-Loci. Vortrag zur 89. Jahrestagung der Kinderheilkunde Würzburg. Monatsschrift der Kinderheilkunde, 1993,141: (Supplement 1) 051 .
  5. I. Foeldvari, N. Birdi, P.B. Dent, R. Elborgh, F. Falcini, R. Häfner, R. Joos, A.M. Prieur, K. Rostropowicz-Denisiewicz, A. Savolainen, A. Siamopoulou-Mayridou, F. Zulian, R.E. Petty: Outcome of progressive systemic sclerosis (PSS) in childhood: Results of a multi-national questionnaire. (präsentiert zur “3. European Conference on Pediatric Diseases and Allied Disorders, 9/1995; Gent, Belgium. Clin Exp Rheumatol 1995;13: 554.
  6. I. Foeldvari, U. N. Birdi, P.B. Dent, R. Elborgh, F Falcini, R. Häfner, R. Joos, A.M. Prieur, K. Rostropowicz-Denisiewicz, A. Savolainen, A Siamopoulou-Mayridou, F. Zulian, R.E. Petty: Progressive Systemische Sklerodermie (PSS) bei 94 Kindern: Ergebnis einer multinationalen Studie. Vortrag zur 5. Jahrestagung der Deutschen Gesellschaft für Kinderrheumatologie, Freiburg i.Br., 1995, Monatsschrift Kinderheilkunde 1995; 143: 1052 V18.
  7. I .Foeldvari, C. Soost, R. Klein, C. Loeliger: Assoziation des Auftretens von Antiphospholipid-Antikörpern mit HLA-Merkmalen bei Kindern mit rheumatologischen Erkrankungen und ihren Eltern. Vortrag zur 6. Jahrestagung der Deutschen Gesellschaft für Kinderrheumatologie, Mühlheim an der Ruhr, 1996. Monatsschrift der Kinderheilkunde 1996; 144:1295.
  8. I. Foeldvari, M. Zhavania, N. Birdi, R.J. Cuttica, S.H.F. de Oliveira, P.B. Dent, R. Elborgh, F. Falcini, G. Ganser, H. Girschick, R. Häfner, R. Joos, W. Kuis, P. Pelkonen, A.M. Prieur, K. Rostropowicz-Denisiewicz, R. Russo, A. Savolainen, A. Siamopoulou-Mayridou, F. Zulian: Günstigere Überlebenschance bei 135 Patienten mit juveniler systemischer Sklerodermie (jSSc): Ergebnisse einer multinationalen Studie. 8. Jahrestagung der Arbeitsgemeinschaft für Kinder- und Jugendmedizin, 10/98 Cottbus.
  9. I. Foeldvari., M. Redegeld, M. Mehrwald, D. Hülsebus, M. Bullinger. Gesundheitsbezogene Lebensqualität von Rheuma-betroffenen Kindern und Jugendlichen aus Elternsicht. Jahrestagung der Arbeitsgemeinschaft Kinder- und Jugendrheumatologie und Pädiatrische Immunologie, Tübingen Mai 2000.
  10. B. Finckh, I. Foeldvari, D. Huelsebus, M. Mehrwald, A. Kohlschütter: Changes of antioxidative status and lipid peroxidation in juvenile idiopathic arthritis over a period of three months. 10th Biennial Meeting of the International Society for Free Radical Research. Abstract No. 002-5 (Reference No.: 100) Kyoto, Japan, 10/2000.
  11. G. Horneff, I. Foeldvari, R.M. Küster, H. Michles, D. Moebius, H. Schmeling, A. Thon: Etanercept for the treatment of juvenile idiopathic arthritis: results of the German registry. Ann Rheum Disease 2002, 61,Suppl 1: 52 – OP 0062.
  12. I. Foeldvari: Steroid induzierte Osteoporose bei Kindern mit kinderheumatologischen Erkrankungen? Ergebnisse einer Pilotstudie. Zeitschrift für Rheumatologie, 2002, 61 (Suppl. 1.): I/64 (PDG 11)
  13. I. Foeldvari: Es zeigt sich eine sehr gute Verträglichkeit von Vioxx? in der Anwendungsbeobachtung. 12. Jahrestagung der Arbeitsgemeinschaft für Kinder- und Jugendrheumatologie. Aktuelle Rheumatologie 2002, 27 :276 (36).
  14. G. Horneff , T. Biedermann, I. Foeldvari, et al. Combination therapy with methotrexat and etanercept compared to etanercept monotherapy. Xth European Pediatric Rheumatology Congress. Clinical Experimental Rheumatology 2003, 21: 540
  15. G. Martini, I. Foeldvari, R.Russo, et al. Juvenile systemic sclerosisand related disorders: an international multicentre data collection of 181 patients. Xth European Pediatric Rheumatology Congress. Clinical Experimental Rheumatology 2003, 21: 551
  16. K. Minden, M. Niewerth, G. Ganser, RM Küster, D. Möbius, I. Foeldvari, A. Zink: Therapiekontinuität bei der juvenilen idiopathischen Arthritis. 13. Jahrestagung der Arbeitsgemeinschaft für Kinder und Jugendrheumatologie. Aktuelle Rheumatologie, 2003, 28: 282, F.6.
  17. I. Foeldvari, A. Wierk. Results of leflunomide (LEF) therapy in patients with juvenile idiopathic arthritis (JIA): A pilot noncontrolled therapeutic intervention. EULAR 2004 , Berlin, Ann Rheum Dis 2004, 61 (Supll 1.): 80 – OP 0076.
  18. I. Foeldvari, A. Wierk. Kann man in der pädiatrischen Population den modifizierten Rodnan Skin Score ohne Adaptation anwenden? Zeitschrift für Rheumatologie 2004, 63: 274- F.3.
  19. N.Ruperto, DJ. Lovell, S. Goodmann, A. Reiff, L. Jung, D.Nmecova, K. Jarosova, AM: Prieur, C. Sandborg, R. Joos, I. Foeldvari, et,al. Preliminary data from the open label phase of he randomized trial of adalimumab in children with juvenile idiopathic arthritis. PRES 2004, Kosice, Slovakia. Clin exp Rheum 2004, 22:522.
  20. I. Foeldvari, A. Wierk: Helathy children have a significantly increased skin score assessed with the modified Rodnan skin score. PRES 2004, Kosice, Slovakia. Clin exp Rheum 2004, 22:527.
  21. N. Ruperto, A. Ravelli, S.Olivieri, E. Silverman, G. espada, D. Mihaylova, S. Pasic, S. Ozen, M. Apaz, B. Bica, D. nemcova, R. Burgos-Varagas, F. Corona, AM. Romicka, J. Consuegra, S. Hagleberg, C Da Silva, C. Coto, Y. Uziel, J. Ros, MI. Gamir, I. Foeldvari, et, al. The validated PRINTO core set and definition of improvement for juvenile systemic lupus erythematosus. PRES 2004, Kosice, Slovakia. Clin exp Rheum 2004, 22:510.
  22. G. Horneff, R. Küster, H. Girschick, I. Foeldvari, D. Moebius. Safety of etanercept for treatment of juvenile idiopathic arthritis (JIA) – data of the German etanercept JIA registry. EULAR 2005, Wien , Österreich. Ann Rheum Dis 2005, 64 , Supplement III: 72 – OP 0048.
  23. C. Boschau, O. Witt, L. Schweigerer, P. Lohse, I. Foeldvari, H. Zappel. Neonatal-onset multisystem inflammatory disease (NOMID): new mutation of the CIAS1 gene and response to interleukin-1 recptor antagonist treatment. 15. Tagung der Arbeitsgemeinschaft für Kinder- nd Jugendrheumatologie, 2005 Dresden. Zeitschrift für Rheumatologie 2005, 64 (Suppl 1): FKJ3-3, I/29.
  24. I. Foeldvari, S. Nielson, J. Kümmerle-Deschner, T. Sauerenman. Ergebnisse der multinationalen Befragung über die Anwendung der Tumor Nekrosis Faktor alpha Blocker in der Behandlung der JIA assoziierten Uveitis. 15. Tagung der Arbeitsgemeinschaft für Kinder- nd Jugendrheumatologie, 2005 Dresden. Zeitschrift für Rheumatologie 2005, 64 (Suppl 1): FKJ3-7, I/30.
  25. M. Niewerth, K. Minden, I. Foeldvari, G. Ganser, A. Zink. Übergewicht – ein Thema bei rheumakranken Kindern und Jugendlichen? Gewichtsstatus bei Patienten mit juveniler idiopathischer Arthritis. 15. Tagung der Arbeitsgemeinschaft für Kinder- nd Jugendrheumatologie, 2005 Dresden. Zeitschrift für Rheumatologie 2005, 64 (Suppl 1): FKJ2-5, I/28.
  26. F. Zulian, P. Woo, B.H. Athreya, R. laxer, T.A. Medsger, T.A. Lehman, M. Matucci-Cerinic, G. Martini, A. Ravelli, R. Russo, R. Cuttica, S.F.K. De Oliveira, C. Denton, I. Foeldvari, N. Ruperto. Preliminary classification criteria for systemic sclerosis in children. XII. European Pediatric Rheumatology Congress, Versaille, Frankreich 2005. Clinical Exp Rheumatol 2005; 23 (Suppl 37): S-47.
  27. G. Horneff, H. Girschick, I. Foeldvari, H. Michels, B. Rogalski, H. Schmeling: Combination therapy with etanercept and methotrexate compared to etanercept monotherapy in patients with juvenile idiopathic arthritis. 2005 Annual Scientific Meeting of the American College or Rheumatology, San Diego, Ca., USA. Arthritis Rheum 2005, 52 (Suppl): A 1955.
  28. N. Ruperto, D.J. Lovell, S. Goodman, A. Reiff, L.Jung, D: Nemcova, K. Jarosova, A. Prieur,C. Sanborg, R. Joos, I. Foeldvari, V. Gerloni, J. Rovensky, J. Bohnsack, K.Minden, L. Wagner-Weiner, R. Vehe, H. Huppertz, G. Horneff,N. Olson, J. Medich, E.H. Giannini, A. Martini: 48 week data from the study of adalimumab in children with juvenile rheumatoid arthritis. Annual European Congress of Rheumatology, 2006, Amsterdam, Holland. Ann Rheum Dis 2006, 65 Suppl II: 56.
  29. I.Foeldvari, A. Heiligenhaus, C.Tappeiner,S. Nielson, N. Tzaribachev, J. Quitsch, F. Dressler, M.O. Hilario, R.M. Küster, M. Borte, H. Mazu, E. Jäger-Roman, A. Wierk: Ergebnisse einer mulitnationalen Befragung zur Anwendung von Cyclopsporinb-A (CSA) in der Behandlung von Uveitis assoziiert mit juvenilen idiopathischen Arthritis (JIA). 16. Jahrestagung der Gessellschaft für Kinder- und Jugendrheumatologie , Leipzig 2006. Kinder- und Jugendmedizin 2006; 6: A 50, Abstact 39.
  30. G. Horneff, I. Foeldvari, J. Roth, H. Michels, M. Borte, H. Schmeling. Efficacy and tolerability of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. 2006 Annual Scientific Meeting of the American College of Rheumatology, Washington. Arth Rheumatism 2006, 54 (Suppl):S327 A 722.
  31. O. Kowal-Bielecka, R. Landews, J. Avouac, S. Chwiesko, L. Miniati, L. Czirjak, P. Clements, C. Denton, D. Farge, K. Fligelstone, I. Foeldvari,… et al. EULA/EUSTAR recommendation for the management of systemic sclerosis. THU0281, EULAR 2007 Barcelona.
  32. I. Foeldvari, C. Wotuers, T. Avcin, F. Zulian. Results of a multinationla survey regarding preferences of paediatric rheumatologists in the treatment of juvenile systemic sclerosis. OPO185, EULAR 2007, Barcelona.
  33. F.Zulian, O.Kowal-Bielecka, I. Miniati, J. Avouac,SChwiesko, A. Aggarwal, BH Atreya, T. Avcin, R. Cuttica, SDKF de Oliveira, G. Higgins, RM Laxer, C. Lindsley, TH Lehman, G Martini, A Ravelli, R Russ, Y Uziel, C Wouters, I Foeldvari, EUSTR/Eular commitess on SSc management recommendations. Preliminary agreement of the Pediatric Rheumatology European Society(PRES) in the EUSTAR/EULAR redommendations for the management of systemic sclerosis in children. OP-17 on the 14 th European Pediatric Rheumatology Congress, Istanbul, Turkey. 2007.
  34. I Foeldvari, C Wouters, T Avcin, F Zulian. Results of a multinational survey regarding preferences of paediatric rheumatologists in the treatment of juvenile systemic sclerosis. OP-19 on the 14 th European Pediatric Rheumatology Congress, Istanbul, Turkey. 2007.
  35. I Foeldvari, A Wierk. Leflunomide is an effective alternative in the treatment for patients with juvenile idiopathic arthritis. OP-30 on the 14 th European Pediatric Rheumatology Congress, Istanbul, Turkey. 2007.
  36. O Distler, D Pittrow, F Behrens, D Huescher, C Denton, I Foeldvari, et al. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: Delphie consensus study with cluster analysis. ACR 2007, Boston. Arthritis Rheumatism 2007, 56 (Suppl): A 2164, S 824
  37. I. Foeldvari. The prospective juvenile systemic sclerosis inceptions cohort. 1st Conference on Translational Research I Pediatric Rheumatology. Genoa , Italy.2008.
  38. D Lovell, R Cuttica, P Woo, G Espada, C Wouters, ED Silverman, Z Balogh, M Henricksen, J Davidson, I Foeldvari, L Imundo, G Simonini, J Oppermann, YK Shen, S Visvanathan, A Fasanmade et al. Long term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course JRA: findings from the open label treatment extension. Annual PRES meeting London, UK 2008.
  39. A randomised trial of 6 months versus 12 months withdrawal of methotrexate in children with juvenile idiopathic arthritis in clinical remission.. D. Foell, N. Wulffraat, L.R. Wedderburn, A. Pistorio, A. Ravelli, V. Stanevicha, D. Mihaylova, V.P.L. Ferriani, F. Kanakoudi Tsakalidou, I. Foeldvari, R. Cuttica, B. Gonzalez4, R. Khubchandani, S.K.F. Oliveira, W. Armbrust, S.M. Garay, J. Vojinovic, X. Norambuena, M. Gamir, J. Garcia Consuegra, L. Lepore, G. Susic, F. Corona4, P. Dolezalova, T. Saurenmann, Y. Uziel, A. Martini, N. Ruperto, for PRINTO
    EULAR 2009 [THU0413], Copenhagen, Denmark.
  40. N. Ruperto, D.J. Lovell, R. Mouy, E. Paz, N. Rubio-Perez, C.A. Silva, C. Abud-Mendoza, R. Burgos-Vargas, V. Gerloni, J.A. Melo-Gomes, C. Saad-Magalhaes, J. Chavez1, C. Huemer, A. Kivitz, F. Blanco, I. Foeldvari, M. Hofer, G. Horneff1, H. Huppertz, C. Job Deslandre, K. Minden, M. Punaro, A. Flores Nunez, L.H. Sigal, A.J. Block, A. Covucci, A. Martini, E.H. Giannini. Long-term safety and efficacy of abatacept in subjects with polyarticular juvenile idiopathich arthritis. OP- 0268 EULAR 2009 [THU0413], Copenhagen. Denmark.
  41. J.B. Kuemmerle Deschner, R. Cartwright, M. Gattorno, F. Zulian, P. Quartier, J. Hoyer, I. Foeldvari, E. Ramos, P.N. Hawkins, K. Leslie, G. Krammer, S. Malfait, R. Preiss, A. Widmer and E. Hachulla. Safety and effecacy of canakinumab in children accross different disease severity and phenotypes of cryopyrin associated periodic syndrome (CAPS): intermin results of an ongoing study. ACR 2009 Philadelphia, USA, Arthritis Rheum 2009, 60: #2056.
  42. P Quartier, E Hachulla, M Gattorno, R Cartwright, I Kone-Paut, F Zulian, E Weisbarth-Riedel, L Lepore, J Hoyer, I Foeldvari, E Ramos, P N Hawkins, K Leslie, G Krammer, R Preiss, A Widmer, J B Kuemmerle-Deschner. Canakinumab (ILARIS®) Provides Rapid Response and Sustained Remission in Children across Different Disease Severity Phenotypes of Cryopyrin Associated Periodic Syndrome (CAPS). ACR 2010. Arth Rheum 2010, 62.
  43. I. Foeldvari, A. Wierk, D. Farge. When is autologous bone marrow transplantation indicated in juvenile systemic sclerosis. Results of a multinational survey of pediatric rheumatologist. 2 nd Systemic Sclerosis World Congress, 02.-04.2012, Madrid . Spain. Rheumatology 2012, Volume 51, Supplement 2; S1.4. ii2.
  44. I Foeldvari . Looking for minimal standards in care of children with localised scleroderma. Resutls of the consensus meeting in Hambug Germany on the 11th of December 2011. DGRH 2012 Bochum
  45. D. J. Lovell1, N. Ruperto2, R. Mouy2, E. Paz2, N. Rubio-Perez2, C. A. Silva2,C. Abud-Mendoza2, R. Burgos-Vargas2, V. Gerloni2, J. A. Melo-Gomes2, C ,Saad-Magalhaes2, J. Chavez2, C. Huemer2, A. Kivitz2, F. Blanco2, I. Foeldvari2, Michael Hofer3, H. Huppertz2, C. Job Deslandre2, K. Minden2, A. Flores Nunez4, A. J. Block5 and A. Martini2. 1Cincinnati Children’s Hospital, Cincinnati, OH, 2PRINTO, IRCCS G. Gaslini, Genoa, Italy, 3Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genoa, Italy, 4PRINTO, IRCCS Hospital para el Nin˜o Poblano, Puebla, Mexico, 5Bristol-Myers Squibb, Princeton, NJ. Cumulative Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis: Results up to 7 Years of Follow-up. Arth Rheum 2012, 64:S 717 A 1679
  46. Seza Özen1, Jasmin Kuemmerle-Deschner2, Luca Cantarini3, Rolando Cimaz4, Pierre Quartier5, Ahmet Gül6, Isabelle Koné-Paut7, Steven Spalding8, Andrew Zeft8, Anna Simon9, Philip Hashkes10, Véronique Hentgen11, Tilmann Kallinich12, Sinisa Savic13, Ivan Foeldvari14, Joost Frenkel15, Uwe Machein16, Avi Livneh17, Helen J. Lachmann18. Patient Journey and Treatment Route to Use of First Biologic in Rare Autoinflammatory Diseases: An International Retrospective Chart Review. EULAR Annual Meeting Paris 2014.
  47. Gerd Horneff*, Sophie Von Stackelberg, Ivan Foeldvari, J-P. Haas, Gerd Ganser, Kirsten Minden, Anton Hospach on behalf of the German and Austrian Collaborative BIKER study group. JADAS REMISSION AND MINIMAL DISEASE ACTIVITY UPON FIRST BIOLOGIC IN JIA. EULAR Annual Meeting Paris 2014.
  48. Gerd Horneff, Ivan Foeldvari, Kirsten Minden, Klaus Tenbrock, Hans I. Huppertz, Ingrid Becker. ANALYSIS OF UVEITIS EVENTS IN THE BIOLOGICS IN PEDIATRIC RHEUMATOLOGY (BIKER)-REGISTRY. EULAR Annual Meeting Paris 2014.
  49. N Ruperto,1 DJ Lovell,2 N Tzaribachev,3 G Vega-Cornejo,4 I Louw,5 A Berman,6 I Calvo,7 R Cuttica,8 G Horneff,9 F Avila-Zapata,10 J Anton,11 D Viola,12 I Foeldvari,13 V Keltsev,14 D Kingsbury,15 X Li,16 M Nys,17 R Wong,16 S Banerjee,16 A. Martini,18 HI Brunner2.  Subcutaneous Abatacept in Patients with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety. EULAR Annual Meeting London 2016.
  50. I Foeldvari* 1 , N Ruperto1 , DJ Lovell2 , G Horneff1 , H-I Huppertz1 , P Quartier3 , G Simonini1 , M Bereswill4 , J Kalabic4 , AMartini1 , HI Brunner2  UVEITIS ASSOCIATED TO POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): DATA FROM STRIVE REGISTRY. PRES Meeting Genua 2016.
  51. Foeldvari 1, J. Klotsche2, O. Kasapcopur3, A. Adrovic3, V. Stanevicha4, M.T. Terreri 5, E. Alexeeva6, M.M. Katsicas 7, R. Cimaz 8, M. Kostik 9, T. Lehman10, W. A. Sifuentes-Giraldo 11, V. Smith12, F. Sztajnbok 13, T. Avcin 14, M. Jose Santos 15, M. Moll 16, D. Nemcova 17, C. Battagliotti18, D. Eleftheriou 19, H. Liora20, M. Janarthanan 21, T. Kallinich 22, J. Lopez23, K.Minden 22, S. Nielsen 24, K. Torok 25, Y.Uziel 26, N. Helmus 1. CHARACTERISTICS OF THE FIRST 97 PATIENTS AT  TIMEPOINT OF FIRST ASSESSMENT INCLUDED IN THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT. WWW.JUVENILESCLERODERMA.COM. DGRH , Stuttgart.  09.09.2017
  52. Ivan Foeldvari, Jordi Anton, Marc Friswell, Blanca Bica, Jaime Innocencio, Rebecca Nicolai, Nicola Helmus. Tocilizumab is a promising treatment option for therapy resistent juvenile localised scleroderma patients. Annual PRES meeting, Athens 2017.
  53. I. Foeldvari 1, J. Klotsche2, O. Kasapcopur3, A. Adrovic3, V. Stanevicha3, K. Torok3, T. Terreri3, E. Alexeeva3, M. Katsikas3, V. Smith3, F. Sztajnbok3, T. Avcin3, R. Cimaz3, J. Anton3, M. Kostik3, T. Lehman3, W.-A. Sifuentes-Giraldo3, S. Appenzeller3, M. Janarthanan3, M. Moll3, D. Nemcova3, M.J. Santos3, C. Battagliotti3, L. Berntson3, J. Brunner3, D. Eleftheriou3, L. Harel3, T. Kallinich3, K. Minden2, S. Nielsen3, Y Uziel3, A. Stevens3, C.Pilkington3, N. Helmus1. Are patients with overlap features different from patients without? Results from the juvenile systemic scleroderma cohort www.juvenile-scleroderma.com. American College of Rheumatology Meeting 2017, Nov 08. San Diego, USA.
  54. S. Özen, E. Ben-Chetrit, I. Foeldvari, G. Amarilyo, H. Ozdogan, S. Vanderschueren, K. Marzan, J. M. Kahlenberg, E. Dekker, F. De Benedetti, I. Koné-Paut. LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH COLCHICINE-RESISTANT FAMILIAL MEDITERRANEAN FEVER: RESULTS FROM THE RANDOMISED PHASE 3 CLUSTER TRIAL, OP 0272. EULAR 2020, 03.-06. June, Frankfurt, Germany (ECongress).
  55. I. Foeldvari, J. Klotsche. Validation of Disease activity measures in patients with juvenile systemic sclerosis. Results from the inception cohort World Scleroderma Congress ECongress 12-14th of July, 2020.
  56. J. B. Kuemmerle-Deschner,  B. Kortus, Goetze, P. Oommen,  A. Janda, J. Rech, T. Kallinich, F. Weller-Heinemann, G. Horneff, I. Foeldvari, C. Schuetz, M. Borte, A. Braner, J. Weber-Arden, N. Blank. OP0092 LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) – 30-MONTH DATA FROM THE RELIANCE REGISTRY. EULAR 2021. E Congress 2-5th of June, 2021
  57. I. Foeldvari, J. Klotsche, O. Kasapcopur, A. Adrovic, K. Torok, M. T. Terreri, A. P. Sakamoto, B. Feldman, V. Stanevicha, J. Anton, F. R. Sztajnbok, R. Khubchandani, E. Alexeeva, M. Katsikas, S. Sawhney, V. Smith, S. Appenzeller, T. Avcin, M. Kostik, T. Lehman, E. Marrani, D. Schonenberg, W. A. Sifuentes-Giraldo, N. Vasquez-Canizares, M. Janarthanan, M. Moll, D. Nemcova, A. Patwardhan, M. J. Santos, C. Battagliotti, L. Berntson, B. Bica, J. Brunner, R. Cimaz, P. Costa Reis, D. Eleftheriou, L. Harel, G. Horneff, S. Johnson, D. Kaiser, T. Kallinich, D. Lazarevic, K. Minden, S. Nielsen, F. Nuruzzaman, S. Opsahl Hetlevik, Y. Uziel, N. Helmus. POS0079 PATIENTS WITH JUVENILE SYSTEMIC SCLEROSIS HAVE A DISTINCT PATTERN OF ORGAN INVOLVEMENT.RESULTS FROM THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT. WWW.JUVENILE-SCLERODERMA.COM,. EULAR 2021. E Congress 2-5th of June, 2021
  58. N. Ruperto, G. Schulert, A. Sproles, S. Thornton, G. Vega Cornejo, J. Anton, R. Cuttica, M. Henrickson, I. Foeldvari, D. Kingsbury, M. Askelson, J. Liu, S. Mukherjee, R. Wong, D. J. Lovell, A. Martini, A. Grom, H. Brunner. POS0076 S100A8/A9 AND S100A12 AS POTENTIAL PREDICTIVE BIOMARKERS OF ABATACEPT RESPONSE IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. EULAR 2021. E Congress 2-5th of June, 2021
  59. A. Zimmer, A. Klein, K. Minden, T. Hospach, F. Weller-Heinemann, J. Kuemmerle-Deschner, M. Fasshauer, N. Hofmann, H. Koessel, I. Foeldvari, S. Mrusek, D. Windschall, N. Onken, M. Hufnagel, D. Foell, N. Brueck, P. T. Oommen, F. Dressler, A. Helling-Bakki, G. Horneff. POS0075 SAFETY AND EFFICACY OF GOLIMUMAB FOR THE TREATMENT OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS – AN UPDATE FROM THE BIKER REGISTRY. EULAR 2021. E Congress 2-5th of June, 2021
  60. N Ruperto1*, I Foeldvari2, E Alexeeva3, N A Ayaz4, I Calvo5, O Kasapcopur4, V Chasnyk6, M Hufnagel7, Z Zuber8, G Schulert9, S Ozen10, A Popov11, A Ramanan12, C Scott13,
    B Sozeri14, E Zholobova15, X Zhu16, S Whelan17, L Pricop16, A Ravelli18, A Martini1,
    D J Lovell19, H I Brunner19 on behalf of PRINTO and PRCSG. Efficacy and Safety of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: Primary Results from a Randomised, Double-blind, Placebo-controlled, Treatment Withdrawal, Phase 3 Study (JUNIPERA). EULAR 2021. E Congress 2-5th of June, 2021
  61. N Ruperto1*, I Foeldvari2, E Alexeeva3, N A Ayaz4, I Calvo5, O Kasapcopur4, V Chasnyk6, M Hufnagel7, Z Zuber8, G Schulert9, S Ozen10, A Popov11, A Ramanan12, C Scott13,
    B Sozeri14, E Zholobova15, X Zhu16, S Whelan17, L Pricop16, A Ravelli18, A Martini1,
    D J Lovell19, H I Brunner19 on behalf of PRINTO and PRCSG. Efficacy and Safety of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: Primary Results from a Randomised, Double-blind, Placebo-controlled, Treatment Withdrawal, Phase 3 Study (JUNIPERA). PRES Virtual Congress . 19.-21.09.2021
  62. Ivan Foeldvari1, Jens Klotsche2, Ozgur Kasapcopur3, Amra Adrovic3, Maria Teresa Terreri4, Ana Paula Sakamoto4, Valda Stanevicha5, Jordi Anton6, Brian M. Feldman7, Flavio Sztajnbok8, Raju Khubchandani9, Ekaterina Alexeeva10, Maria Katsicas11, Sujata Sawhney12, Vanessa Smith13, Simone Appenzeller14, Tadej Avcin15, Mikhail Kostik16, Thomas Lehman17, Edoardo Marrani18, Dieneke Schonenberg-Meinema19, Walter-Alberto Sifuentes-Giraldo20, Natalia Vasquez-Canizares21, Mahesh Janarthanan22, Monika Moll23, Dana Nemcova24, Anjali Patwardhan25, Maria Jose Santos26, Cristina Battagliotti27, Lillemor Berntson28, Blanca Bica29, Jürgen Brunner30, Rolando Cimaz31, Patricia Costa-Reis32, Despina Eleftheriou33, Liora Harel34, Gerd Horneff35,36, Sindhu R. Johnson37, Daniela Kaiser38, Tilmann Kallinich39, Dragana Lazarevic40, Kirsten Minden39, Susan Nielsen41, Farzana Nuruzzaman422, Siri Opsahl Hetlevik43, Yosef Uziel44, Nicola Helmus1, Kathryn S. Torok45. Male juvenile systemic sclerosis patients have more severe disease: results from the international juvenile scleroderma inception cohort. PRES Virtual Congress . 19.-21.09.202
  63. Ivan Foeldvari2, Bernd Hinrichs1, Ekaterina Alexeeva3, Jordi Anton3, Simone Appenzeller3, Lillemor Berntson3, Jürgen Brunner3, Patricia Costa Reis3, Brian Feldman3, Gerd Horneff3, Mahesh Janarthanan 3, Tilmann Kallinich3, Ozgur Kasapcopur3, Raju Khubchandani3, Mikhail Kostik3, Thomas Lehman3, Edoardo Marrani3, Susan Nielsen3, Farzana Nuruzzaman3, Anjali Patwardhan3, Maria Jose Santos3, Dieneke Schonenberg-Meinema3, Vanessa Smith3, Valda Stanevicha3, Flavio Sztajnbok3, Maria Teresa Terreri3, Kathryn Torok3, Yosef Uziel 3, NIcola HelmusHOW IS PULMONARY FUNCTION ASSESSED IN JUVENILE SYSTEMIC SCLERODERMAPATIENT? DO WE HAVE A GOOD CLINICAL STANDARD? RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT- WWW.JUVENILE-SCLERODERMA.COM. PRES Virtual Congress . 19.-21.09.2021
  64. Ivan Foeldvari1, Jens Klotsche2, Ozgur Kasapcopur3, Amra Adrovic3, Kathryn Torok3, Maria T. Terreri3, Ana Paula Sakamoto3, Flávio R. Sztajnbok3, Brian Feldman3, Valda Stanevicha3, Jordi Anton3, Raju Khubchandani3, Ekaterina Alexeeva3, Sindhu Johnson3, Maria Katsikas3, Sujata Sawhney3, Vanessa Smith3, Simone Appenzeller3, Tadej Avcin3, Mikhail Kostik3, Thomas Lehman3, Edoardo Marrani3, Dieneke Schonenberg-Meinema3, Walter Alberto Sifuentes-Giraldo3, Natalia Vasquez-Canizares3, Mahesh Janarthanan3, Hana Malcova3, Monika Moll3, Dana Nemcova3, Anjali Patwardhan3, Maria Jose Santos3, Cristina Battagliotti3, Lillemor Berntson3, Blanca Bica3, Juergen Brunner3, Rolando Cimaz3, Patricia Costa Reis3, Despina Eleftheriou3, Liora Harel3, Gerd Horneff3, Daniela Kaiser3, Tilmann Kallinich3, Dragana Lazarevic3, Kirsten Minden2, Susan Nielsen3, Farzana Nuruzzaman3, Siri Opsahl Hetlevik3, Yosef Uziel3, Nicola Helmus1 Patients with juvenile systemic sclerosis have a distinct pattern of organ involvement results from the juvenile systemic sclerosis inception cohort. . PRES Virtual Congress . 19.-21.09.2021
  65. Ivan Foeldvari1, Jens Klotsche2, Ozgur Kasapcopur3, Amra Adrovic3, Maria Teresa Terreri4, Ana Paula Sakamoto4, Valda Stanevicha5, Jordi Anton6, Brian M. Feldman7, Flavio Sztajnbok8, Raju Khubchandani9, Ekaterina Alexeeva10, Maria Katsicas11, Sujata Sawhney12, Vanessa Smith13, Simone Appenzeller14, Tadej Avcin15, Mikhail Kostik16, Thomas Lehman17, Edoardo Marrani18, Dieneke Schonenberg-Meinema19, Walter-Alberto Sifuentes-Giraldo20, Natalia Vasquez-Canizares21, Mahesh Janarthanan22, Monika Moll23, Dana Nemcova24, Anjali Patwardhan25, Maria Jose Santos26, Cristina Battagliotti27, Lillemor Berntson28, Blanca Bica29, Jürgen Brunner30, Rolando Cimaz31, Patricia Costa-Reis32, Despina Eleftheriou33, Liora Harel34, Gerd Horneff35,36, Sindhu R. Johnson37, Daniela Kaiser38, Tilmann Kallinich39, Dragana Lazarevic40, Kirsten Minden39, Susan Nielsen41, Farzana Nuruzzaman422, Siri Opsahl Hetlevik43, Yosef Uziel44, Nicola Helmus1, Kathryn S. Torok45. Male juvenile systemic sclerosis patients have more severe disease: results from the international juvenile scleroderma inception cohort. Kongress der Deutschen Gesellschaft für Kinder- und Jugendrheumatologie. Berlin, 06-09.10.2021
Letters

Stand: 12.09.2021